Molecular mechanisms, lipoprotein abnormalities and atherogenicity of hyperalphalipoproteinemia

Atherosclerosis

Volumn 152, Issue 2, 2000, Pages 271-285

  Yamashita, Shizuya ^a   Maruyama, Takao ^a   Hirano, Ken Ichi ^a   Sakai, Naohiko ^a   Nakajima, Norimichi ^b   Matsuzawa, Yuji ^a  

^a Graduate School of Medicine   (Japan)

^b Nakajima Clinic   (Japan)

Author keywords

Atherosclerosis; Cholesteryl ester transfer protein deficiency; Hyperalphalipoproteinemia; Reverse cholesterol transport

Indexed keywords

CHOLESTEROL ESTER TRANSFER PROTEIN; INTERMEDIATE DENSITY LIPOPROTEIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ATHEROGENESIS; ATHEROSCLEROSIS; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; HUMAN; HYPERLIPOPROTEINEMIA; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; RABBIT; REVIEW; TRANSGENIC MOUSE;

ANIMALS; APOLIPOPROTEINS A; ARTERIOSCLEROSIS; CARRIER PROTEINS; CHOLESTEROL ESTER TRANSFER PROTEINS; GENETIC PREDISPOSITION TO DISEASE; GLYCOPROTEINS; HUMANS; HYPERLIPOPROTEINEMIAS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL;

EID: 0033816683     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(00)00574-8     Document Type: Review

References (120)

1. Tall A. Lipid transfer proteins. Annu. Rev. Biochem. 64:1995;235-257.
2. Lagrost L. Regulation of cholesteryl ester transfer protein (CETP) activity; review of in vitro and in vivo studies. Biochem. Biophys. Acta. 1215:1994;209-236.
3. Acton S., Rigotti A., Landschulz K.T., Xu S., Hobbs H.H., Krieger M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science. 271:1996;518-520.
4. Glomset J.A. The plasma lecithin:cholesterol acyltransferase reaction. J. Lipid Res. 9:1968;155-167.
5. Fielding C.J., Fielding P.E. Molecular physiology of reverse cholesterol transport. J. Lipid Res. 36:1995;211-228.
6. Hill S.A., McQueen M.J. Reverse cholesterol transport - a review of the process and its clinical implications. Clin. Biochem. 30:1997;517-525.
7. Castro G.R., Fielding C.J. Early incorporation of cell-derived cholesterol into pre-beta-migrating high-density lipoprotein. Biochemistry. 27:1988;25-29.
8. Barrans A., Jaspard B., Barbaras R., Chap H., Perret B., Collet X. Pre-beta HDL: structure and metabolism. Biochem. Biophys. Acta. 1300:1996;73-85.
9. Rothblat G.H., de la Llera-Moya M., Atger V., Kellner-Weibel G., Williams D.L., Phillips M.C. Cell cholesterol efflux: integration of old and new observations provides new insights. J. Lipid Res. 40:1999;781-796.
10. Fidge N.H. High density lipoprotein receptors, binding proteins, and ligands. J. Lipid Res. 40:1999;187-201.
11. Ji Y., Jian B., Wang N., Sun Y., de la Llera Moya M., Phillips M.C., Rothblat G.H., Swaney J.B., Tall A.R. Scavenger receptor BI promotes high density lipoprotein-mediated cellular cholesterol efflux. J. Biol. Chem. 272:1997;20982-20985.
12. Hirano K., Yamashita S., Nakagawa Y., Ohya T., Matsuura F., Tsukamoto K., Okamoto Y., Matsuyama A., Matsumoto K., Miyagawa J., Matsuzawa Y. Expression of human scavenger receptor class B type I in cultured human monocyte-derived macrophages and atherosclerotic lesions. Circ. Res. 85:1999;108-116.
13. Brooks-Wilson A., Marcil M., Clee S.M., Zhang L.-H., Roomp K., van Dam M., Yu L., Brewer C., Collins J.A., Molhuizen H.O.F., Loubser O., Ouelette B.F.F., Fichter K., Ashbourne-Excoffon K.J.D., Sensen C.W., Scherer S., Mott S., Denis M., Martindale D., Frohlich J., Morgan K., Koop B., Pimstone S., Kastelein J.J., Genest J. Jr, Hayden M.R. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat. Genet. 22:1999;336-345.
14. Bodzioch M., Orso E., Klucken J., Langmann T., Bottcher A., Diederich W., Drobnik W., Barlage S., Buchler C., Porsch-Ozcurumez M., Kaminski W.E., Hahmann H.W., Oette K., Rothe G., Aslanidis C., Lackner K.J., Schmitz G. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat. Genet. 22:1999;347-351.
15. Rust S., Rosier M., Funke H., Real J., Amoura Z., Piette J.C., Deleuze J.F., Brewer H.B., Duverger N., Denefle P., Assmann G. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat. Genet. 22:1999;352-355.
16. Glueck C.J., Gartside P., Fallat R.W., Sielski J., Steiner P.M. Longevity syndromes; familial hypobeta and familial hyperalphalipoproteinemia. J. Lab. Clin. Med. 88:1976;941-957.
17. Matsuzawa Y., Yamashita S., Kameda K., Kubo M., Tarui S., Hara I. Marked hyper-HDL2-cholesterolemia associated with premature corneal opacity; a case report. Atherosclerosis. 62:1986;117-121.
18. Matsuzawa Y., Yamashita S., Funahashi T., Yamamoto A., Tarui S. Selective reduction of cholesterol in HDL2 fraction by probucol in familial hypercholesterolemia and hyper HDL2 cholesterolemia with abnormal cholesteryl ester transfer. Am. J. Cardiol. 62:1988;66B-72B.
19. Groener J.E.M., Da Col P.G., Kostner G.M. A hyperalphalipoproteinemic family with normal cholesteryl ester transfer/exchange activity. Biochem. J. 242:1987;27-32.
20. Patsch W., Kuisk I., Glueck C., Schonfeld G. Lipoproteins in familial hyperalphalipoproteinemia. Arteriosclerosis. 1:1981;156-161.
21. Hegele R.A., Little J.A., Vezina C., Maguire G.F., Tu L., Wolever T.S., Jenkins D.J., Connelly P.W. Hepatic lipase deficiency. Clinical, biochemical, and molecular genetic characteristics. Arterioscler. Thromb. 13:1993;720-728.
22. Brand K., Dugi K.A., Brunzell J.D., Nevin D.N., Santamarina-Fojo S. A novel A→G mutation in intron I of the hepatic lipase gene leads to alternative splicing resulting in enzyme deficiency. J. Lipid Res. 37:1996;1213-1223.
23. Breckenridge W.C., Little J.A., Alaupovic P., Wang C.S., Kuksis A., Kakis G., Lindgren F., Gardiner G. Lipoprotein abnormalities associated with a familial deficiency of hepatic lipase. Atherosclerosis. 45:1982;161-179.
24. Rader D.J., Schaefer J.R., Lohse P., Ikewaki K., Thomas F., Harris W.A., Zech L.A., Dujovne C.A., Brewer H.B. Jr. Increased production of apolipoprotein A-I associated with elevated plasma levels of high-density lipoproteins, apolipoprotein A-I, and lipoprotein A-I in a patient with familial hyperalphalipoproteinemia. Metabolism. 42:1993;1429-1434.
25. Schmidt H.H., Gregg R.E., Tietge U.J., Beisiegel U., Zech L.A., Brewer H.B. Jr, Manns M.P., Bojanovski D. Upregulated synthesis of both apolipoprotein A-I and apolipoprotein B in familial hyperalphalipoproteinemia and hyperbetalipoproteinemia. Metabolism. 47:1998;1160-1166.
26. Kobayashi J., Nishide T., Shinomiya M., Sasaki N., Shirai K., Saito Y., Yoshida S. A familial hyperalphalipoproteinemia with low uptake of high density lipoproteins into peripheral lymphocytes. Atherosclerosis. 73:1988;105-111.
27. Pagani F., Sidoli A., Giudici G.A., Barenghi L., Vergani C., Baralle F.E. Human apolipoprotein A-I gene promoter polymorphism; association with hyperalphalipoproteinemia. J. Lipid Res. 31:1990;1371-1377.
28. Minnich A., DeLangavant G., Lavigne J., Roederer G., Lussier-Cacan S., Davignon J. G→A substitution at position-75 of the apolipoprotein A-I gene promoter. Evidence against a direct effect on HDL cholesterol levels. Arterioscler. Thromb. Vasc. Biol. 15:1995;1740-1745.
29. von Eckardstein A., Holz H., Sandkamp M., Weng W., Funke H., Assmann G. Apolipoprotein C-III (Lys58→Glu). Identification of an apolipoprotein C-III variant in a family with hyperalphalipoproteinemia. J. Clin. Invest. 87:1991;1724-1731.
30. Giziano J.M., Buring J.E., Breslow J.L., Goldhaber S.Z., Rosner B., VanDenburgh M., Willett W., Hennekens C.H. Moderate alcohol intake, increased levels of high-density lipoprotein and its subfractions, and decreased risk of myocardial infaction. N. Engl. J. Med. 329:1993;1829-1834.
31. Hannuksela M., Marcel Y.L., Kesaniemi Y.A., Savolainen M.J. Reduction in the concentration and activity of plasma cholesteryl ester transfer protein by alcohol. J. Lipid Res. 33:1992;737-744.
32. Hirano K., Matsuzawa Y., Sakai N., Hiraoka H., Nozaki S., Funahashi T., Yamashita S., Kubo M., Tarui S. Polydisperse low density lipoproteins in hyperalphalipoproteinemic chronic alcohol drinkers in association with marked reduction of cholesteryl ester transfer protein activity. Metabolism. 41:1992;1313-1318.
33. Hirano K., Yamashita S., Sakai N., Hiraoka H., Ueyama Y., Funahashi T., Matsuzawa Y. Low-density lipoproteins in hyperalphalipoproteinemic heavy alcohol drinkers have reduced affinity for the low-density lipoprotein receptor. Clin. Biochem. 25:1992;357-362.
34. Hiraoka H., Yamashita S., Matsuzawa Y., Kubo M., Nozaki S., Sakai N., Hirano K., Kawata S., Tarui S. Decrease of hepatic triglyceride lipase and increase of cholesteryl ester transfer protein in patients with primary biliary cirrhosis-Relation to the abnormalities in high density lipoprotein. Hepatology. 18:1993;103-110.
35. Hiraoka H. Impairment of the reverse cholesterol transport system associated with primary biliary cirrhosis. Med. J. Osaka Univ. 43:1991;399-408.
36. Demacker P.N., Jansen R.T., Hijmans A.G., van Gorp H.P. A case of hyperalphalipoproteinemia associated with albumin complexing. Atherosclerosis. 111:1994;13-23.
37. Breslow JL. Familial disorders of high-density lipoprotein metabolism. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The Metabolic and Molecular Bases of Inherited Disease. 7th ed New York: McGraw-Hill, 1995: 2031-52.
38. Milano carriers and transgenic mice. Arterioscler. Thromb. Vasc. Biol. 19:1999;1257-1262.
39. Milano dimer. Biochemistry. 38:1999;16307-16314.
40. Shah P.K., Nilsson J., Kaul S., Fishbein M.C., Ageland H., Hamsten A., Johansson J., Karpe F., Cercek B. Effects of recombinant apolipoprotein A-I (Milano) on aortic atherosclerosis in apolipoprotein E-deficient mice. Circulation. 97:1998;780-785.
41. Franceschini G., Sirtori M., Vaccarino V., Gianfranceschi G., Rezzonico L., Chiesa G., Sirtori C.R. Mechanisms of HDL reduction after probucol. Changes in HDL subfractions and increased reverse cholesteryl ester transfer. Arteriosclerosis. 9:1989;462-469.
42. Ishigami M., Yamashita S., Sakai N., Hirano K.I., Arai T., Maruyama T., Takami S., Koyama M., Kameda-Takemura K., Matsuzawa Y. High-density lipoproteins from probucol-treated patients have increased capacity to promote cholesterol efflux from mouse peritoneal macrophages loaded with acetylated low-density lipoproteins. Eur. J. Clin. Invest. 27:1997;285-292.
43. Walsh A., Ito Y., Breslow J.L. High levels of human apolipoprotein A-I in transgenic mice result in increased plasma levels of small high density lipoprotein (HDL) particles comparable to human HDL3. J. Biol. Chem. 264:1989;6488-6494.
44. Rubin E.M., Ishida B.Y., Clift S.M., Krauss R.M. Expression of human apolipoprotein A-I in transgenic mice results in reduced plasma levels of murine apolipoprotein A-I and the appearance of two new high density lipoprotein size classes. Proc. Natl. Acad. Sci. USA. 88:1991;434-438.
45. Rubin E.M., Krauss R.M., Spangler E.A., Verstuyft J.G., Clift S.M. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein A-I. Nature. 353:1991;265-267.
46. Williamson R., Lee D., Hagaman J., Maeda N. Marked reduction of high density lipoprotein cholesterol in mice genetically modified to lack apolipoprotein A-I. Proc. Natl. Acad. Sci. USA. 89:1992;7134-7138.
47. Li H., Reddick R.L., Maeda N. Lack of apo A-I is not associated with increased susceptibility to atherosclerosis in mice. Arterioscler. Thromb. 13:1993;1814-1821.
48. Schultz J.R., Verstuyft J.G., Gong E.L., Nichols A.V., Rubin E.M. Protein composition determines the anti-atherogenic properties of HDL in trangenic mice. Nature. 365:1993;761-764.
49. Warden C.H., Hedrick C.C., Qiao J.H., Castellani L.W., Lusis A.J. Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II. Science. 261:1993;469-472.
50. Vaisman B.L., Klein H.G., Rouis M., Berard A.M., Kindt M.R., Talley G.D., Meyn S.M., Hoyt R.F. Jr, Marcovina S.M., Albers J.J., Hoeg J.M., Brewer H.B. Jr, Santamarina-Fojo S. Overexpression of human lecithin cholesterol acyltransferase leads to hyperalphalipoproteinemia in transgenic mice. J. Biol. Chem. 270:1995;12269-12275.
51. Berard A.M., Foger B., Remaley A., Shamburek R., Vaisman B.L., Talley G., Paigen B., Hoyt R.F. Jr, Marcovina S., Brewer H.B. Jr, Santamarina-Fojo S. High plasma HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressing lecithin-cholesteryl acyltransferase. Nat. Med. 3:1997;744-749.
52. Brousseau M.E., Santamaria-Fojo S., Zech L.A., Berard A.M., Vaisman B.L., Meyn S.M., Powell D., Brewer H.B. Jr, Hoeg J.M. Hyperalphalipoproteinemia in human lecithin cholesterol acyltransferase transgenic rabbits. In vivo apolipoprotein A-I catabolism is delayed in a gene dose-dependent manner. J. Clin. Invest. 97:1996;1844-1851.
53. Hoeg J.M., Santamarina-Fojo S., Berard A.M., Cornhill J.F., Herderick E.E., Feldman S.H., Haudenschild C.C., Vaisman B.L., Hoyt R.F. Jr, Demosky S.J. Jr, Kauffman R.D., Hazel C.M., Marcovina S.M., Brewer H.B. Jr. Overexpression of lecithin:cholesterol acyltransferase in transgenic rabbits prevents diet-induced atherosclerosis. Proc. Natl. Acad. Sci. USA. 93:1996;11448-11453.
54. Sakai N., Vaisman B.L., Koch C.A., Hoyt R.F. Jr, Meyn S.M., Talley G.D., Paiz J.A., Brewer H.B. Jr, Santamarina-Fojo S. Targeted disruption of the mouse lecithin:cholesterol acyltransferase (LCAT) gene. Generation of a new animal model for human LCAT deficiency. J. Biol. Chem. 272:1997;7506-7510.
55. Sakai N., Vaisman B.L., Koch C.A., Paiz J.A., Brewer H.B. Jr, Santamarina-Fojo S., Paigen B. Analysis of aortic atherosclerosis and glomerulosclerosis in LCAT knockout mice. Circulation. 96:1997;I-229.
56. Busch S.J., Barnhart R.L., Martin G.A., Fitzgerald M.C., Yates M.T., Mao S.J., Thomas C.E., Jackson R.L. Human hepatic triglyceride lipase expression reduces high density lipoprotein and aortic cholesterol in cholesterol-fed transgenic mice. J. Biol. Chem. 269:1994;16376-16382.
57. Fan J., Wang J., Bensadoun A., Lauer S.J., Dang Q., Mahley R.W., Taylor J.M. Overexpression of hepatic lipase in transgenic rabbits leads to a marked reduction of plasma high density lipoproteins and intermediate density lipoproteins. Proc. Natl. Acad. Sci. USA. 91:1994;8724-8728.
58. Taylor J.M., Fan J. Transgenic rabbit models for the study of atherosclerosis. Frontiers Biosci. 2:1997;298-308.
59. Agellon L., Quinet E., Gillette T., Drayna D., Brown M., Tall A.R. Organization of the human cholesteryl ester transfer protein gene. Biochemistry. 29:1990;1372-1376.
60. Agellon L.B., Walsh A., Hayek T., Moulin P., Jiang X.C., Shelanski S.A., Breslow J.L., Tall A.R. Reduced high density lipoprotein cholesterol in human cholesteryl ester transfer protein transgenic mice. J. Biol. Chem. 266:1991;10796-10801.
61. Marotti K.R., Castle C.K., Murray R.W., Rehberg E.F., Polites H.G., Melchior G.W. The role of cholesteryl ester transfer protein in primate apolipoprotein A-I metabolism; insights from studies with transgenic mice. Arterioscler. Thromb. 12:1992;736-744.
62. Marotti K.R., Castle C.K., Boyle T.P., Lin A.H., Murray R.W., Melchior G.W. Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Nature. 364:1993;73-75.
63. Jiang X.C., Agellon L.B., Walsh A., Breslow J.L., Tall A. Dietary cholesterol increases transcription of the human cholesteryl ester transfer protein gene in transgenic mice; dependence on natural flanking sequences. J. Clin. Invest. 90:1992;1290-1295.
64. Hayek T., Azrolan N., Verdery R.B., Walsh A., Chajek-Shaul T., Agellon L.B., Tall A.R., Breslow J.L. Hypertriglyceridemia and cholesteryl ester transfer protein interact to dramatically alter high density lipoprotein levels, particle sizes, and metabolism; studies in transgenic mice. J. Clin. Invest. 92:1993;1143-1152.
65. Hayek T., Masucci-Magoulas L., Jiang X., Walsh A., Rubin E., Breslow J.L., Tall A.R. Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene. J. Clin. Invest. 96:1995;2071-2074.
66. Foger B., Chase M., Amar M.J., Vaisman B.L., Shamburek R.D., Paigen B., Fruchart-Najib J., Paiz J.A., Koch C.A., Hoyt R.F., Brewer H.B. Jr, Santamarina-Fojo S. Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterolacyltransferase transgenic mice. J. Biol. Chem. 274:1999;36912-36920.
67. Kozarsky K.F., Donahee M.H., Rigotti A., Iqbal S.N., Edelman E.R., Krieger M. Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels. Nature. 387:1997;414-417.
68. Wang N., Arai T., Ji Y., Rinninger F., Tall A.R. Liver-specific overexpression of scavenger receptor BI decreases levels of very low density lipoprotein apo B, low density lipoprotein apo B, and high density lipoprotein in transgenic mice. J. Biol. Chem. 273:1998;32920-32926.
69. Kozarsky K.F., Donahee M.H., Glick J.M., Krieger M., Rader D.J. Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse. Arterioscler. Thromb. Vasc. Biol. 20:2000;721-727.
70. Ueda Y., Royers L., Gong E., Zhang J., Cooper P.N., Francone O., Rubin E.M. Lower plasma levels and accelerated clearance of plasma high density lipoprotein (HDL) band non-HDL cholesterol in scavenger receptor class B type I transgenic mice. J. Biol. Chem. 274:1999;7165-7171.
71. Ueda Y, Gong E, Royer L, Cooper PN, Francone OL, Rubin EM. Relationship between Expression Levels and Atherogenesis in Scavenger Receptor Class B, Type I Transgenics. J Biol Chem 2000;275:20368-73.
72. Arai T., Wang N., Bezouevski M., Welch C., Tall A.R. Decreased atherosclerosis in heterozygous low density lipoprotein receptor-deficient mice expressing the scavenger receptor BI transgene. J. Biol. Chem. 274:1999;2366-2371.
73. Rigotti A., Trigatti B.L., Penman M., Rayburn H., Herz J., Krieger M. A targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key role in HDL metabolism. Proc. Natl. Acad. Sci. USA. 94:1997;12610-12615.
74. Varban M.L., Rinninger F., Wang N., Fairchild-Huntress V., Dunmore J.H., Fang Q., Gosselin M.L., Dixon K.L., Deeds J.D., Acton S.L., Tall A.R., Huszar D. Targeted mutation reveals a central role for SR-BI in hepatic selective uptake of high density lipoprotein cholesterol. Proc. Natl. Acad. Sci. USA. 95:1998;4619-4624.
75. Trigatti B., Rayburn H., Vinals M., Braun A., Miettinen H., Penman M., Hertz M., Schrenzel M., Amigo L., Rigotti A., Krieger M. Influence of the high density lipoprotein receptor SR-BI on reproductive and cardiovascular pathophysiology. Proc. Natl. Acad. Sci. USA. 96:1999;9322-9327.
76. Huszar D., Varban M.L., Rinninger F., Feeley R., Arai T., Fairchild-Huntress V., Donovan M.J., Tall A.R. Increased LDL cholesterol and atherosclerosis in LDL receptor-deficient mice with attenuated expression of scavenger receptor B1. Arterioscler. Thromb. Vasc. Biol. 20:2000;1068-1073.
77. Brown M.L., Inazu A., Hesler C.B., Agelon L.B., Mann C., Whitlock M.T., Marcel Y.L., Milne R.W., Koizumi J., Mabuchi H., Takeda R., Tall A.R. Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins. Nature. 342:1989;448-451.
78. Yamashita S., Hui D.Y., Wetterau J.R., Sprecher D.L., Harmony J.A.K., Matsuzawa Y., Tarui S. Total deficiency of plasma cholesteryl ester transfer protein in subjects homozygous and heterozygous for the intron 14 splicing defect. Biochem. Biophys. Res. Commun. 170:1990;1346-1351.
79. Inazu A., Brown M.L., Hesler C.B., Agellon L.B., Koizumi J., Takata K., Maruyama Y., Mabuchi H., Tall A.R. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N. Engl. J. Med. 323:1990;1234-1238.
80. Hirano K., Yamashita S., Funahashi T., Sakai N., Menju M., Ishigami M., Hiraoka H., Takemura K., Tokunaga K., Matsuzawa Y. Frequency of intron 14 splicing defect of cholesteryl ester transfer protein gene in the Japanese general population. Atherosclerosis. 100:1993;85-90.
81. Takahashi K., Jiang X.-C., Sakai N., Yamashita S., Hirano K., Bujo H., Yamazaki H., Kusunoki J., Miura T., Kussie P., Matsuzawa Y., Saito Y., Tall A. A missense mutation in the cholesteryl ester transfer protein gene with dominant effects on plasma high density lipoproteins. J. Clin. Invest. 92:1993;2063-2064.
82. Sakai N., Yamashita S., Hirano K., Menju M., Arai T., Kobayashi K., Ishigami M., Yoshida Y., Hoshino T., Nakajima N., Kameda-Takemura K., Matsuzawa Y. Frequency of exon 15 missense mutation (442D:G) in cholesteryl ester transfer protein gene in hyperalphalipoproteinemic Japanese subjects. Atherosclerosis. 114:1995;139-145.
83. Inazu A., Jiang X., Haraki T., Yagi K., Kamon N., Koizumi J., Mabuchi H., Takeda R., Takata K., Moriyama Y., Doi M., Tall A.R. Genetic cholesteryl ester transfer protein deficiency caused by two prevalent mutations as a major determinant of increased levels of high density lipoprotein cholesterol. J. Clin. Invest. 94:1994;1872-1882.
84. Gotoda T., Kinoshita M., Shimano H., Harada K., Shimada M., Ohsuga J., Teramoto T., Yazaki Y., Yamada N. Cholesteryl ester transfer protein deficiency caused by a nonsense mutation detected in the patient's macrophage mRNA. Biochem. Biophys. Res. Commun. 194:1993;519-524.
85. Arai T., Yamashita S., Sakai N., Hirano K., Okada S., Ishigami M., Maruyama T., Yamane M., Kobayashi H., Nozaki S., Funahashi T., Kameda-Takemura K., Nakajima N., Matsuzawa Y. A novel nonsense mutation (G181X) in the human cholesteryl ester transfer protein gene in Japanese hyperalphalipoproteinemic subjects. J. Lipid Res. 37:1996;2145-2154.
86. Sakai N., Santamarina-Fojo S., Yamashita S., Matsuzawa Y., Brewer H.B. Jr. Exon 10 skipping caused by intron 10 splice donor site mutation in cholesteryl ester transfer protein gene results in abnormal downstream splice site selection. J. Lipid Res. 37:1996;2065-2073.
87. Funke H., Wiebusch H., Fuer L., Muntoni S., Schulte H., Assmann G. Identification of mutations in the cholesteryl ester transfer protein in Europeans with elevated high density lipoprotein cholesterol. Circulation. 90:(Part 2):1994;241.
88. Teh E.M., Dolphin P.J., Breckenridge W.C., Tan M.-H. Human plasma CETP deficiency; identification of a novel mutation in exon 9 of the CETP gene in a Caucasian subject from North America. J. Lipid Res. 39:1998;442-456.
89. Hill S.A., Nazir D.J., Jayaratne P., Bamford K.S., McQueen M.J. Mutations in cholesteryl ester transfer protein and hepatic lipase in a North American population. Clin. Biochem. 30:1997;413-418.
90. Ritsch A., Drexel H., Amann F.W., Pfeifhofer C., Patsch J.R. Deficiency of cholesteryl ester transfer protein. Description of the molecular defect and the dissociation of cholesteryl ester and triglyceride transport in plasma. Arterioscler. Thromb. Vasc. Biol. 17:1997;3433-3441.
91. Tollefson J.H., Albers J.J. Isolation, characterization, and assay of plasma lipid transfer proteins. Methods Enzymol. 129:1986;797-816.
92. Kato H., Nakanishi T., Arai H., Nishida H.I., Nishida T. Purification, microheterogeneity, and stability of human lipid transfer protein. J. Biol. Chem. 264:1989;4082-4087.
93. Marcel Y.L., McPherson R., Hogue M., Czarnecka H., Zawadzki Z., Weech P.K., Whitlock M.E., Tall A.R., Milne R.W. Distribution and concentration of cholesteryl ester transfer protein in plasma of normolipidemic subjects. J. Clin. Invest. 85:1990;10-17.
94. Fukasawa M., Arai H., Inoue K. Establishment of anti-human cholesteryl ester transfer protein monoclonal antibodies and radioimmunoassaying of the level of cholesteryl ester transfer protein in human plasma. J. Biochem. 111:1992;696-698.
95. Kurasawa T., Yokoyama S., Miyake Y., Yamaura T., Yamamoto A. Deficiency of serum cholesteryl ester transfer between high and low density lipoproteins in human serum and a case with decreased transfer rate in association with hyperalphalipoproteinemia. J. Biochem. 98:1985;1499-1508.
96. Koizumi J., Mabuchi H., Yoshimura A., Michishita I., Takeda M., Itoh H., Sakai Y., Sakai T., Ueda K., Takeda R. Deficiency of serum cholesteryl-ester transfer activity in patients with familial hyperalphalipoproteinemia. Atherosclerosis. 58:1985;175-186.
97. Yamashita S., Matsuzawa Y., Okazaki M., Kako H., Yasugi T., Akioka H., Hirano K., Tarui S. Small polydisperse low density lipoproteins in familial hyperalphalipoproteinemia with complete deficiency of cholesteryl ester transfer activity. Atherosclerosis. 70:1988;7-12.
98. Yamashita S., Sprecher D.L., Sakai N., Matsuzawa Y., Tarui S., Hui D.Y. Accumulation of apolipoprotein E-rich high density lipoproteins in hyperalphalipoproteinemic human subjects with plasma cholesteryl ester transfer protein deficiency. J. Clin. Invest. 86:1990;688-695.
99. Sakai N., Matsuzawa Y., Hirano K., Yamashita S., Nozaki S., Ueyama Y., Kubo M., Tarui S. Detection of two species of low density lipoprotein particles in cholesteryl ester transfer protein deficiency. Arterioscler. Thromb. 11:1991;71-79.
100. Ishigami M., Yamashita S., Sakai N., Arai T., Hirano K., Hiraoka H., Takemura K., Matsuzawa Y. Large and cholesteryl ester-rich high density lipoproteins in cholesteryl ester transfer protein deficiency can not protect macrophages from cholesterol accumulation induced by acetylated low density lipoproteins. J. Biochem. 116:1994;257-262.
101. Ohta T., Nakamura R., Takata K., Saito Y., Yamashita S., Horiuchi S., Matsuda I. Structural and functional differences of subspecies of apoA-I-containing lipoprotein in patients with plasma cholesteryl ester transfer protein deficiency. J. Lipid Res. 36:1995;696-704.
102. Ikewaki K., Rader D.J., Sakamoto T., Nishiwaki M., Wakimoto N., Schaefer J.R., Ishikawa T., Fairwell T., Zech L.A., Nakamura H., Brewer H.B. Jr. Delayed catabolism of high density lipoprotein apolipoproteins A-I and A-II in human cholesteryl ester transfer protein deficiency. J. Clin. Invest. 92:1993;1650-1658.
103. Ikewaki K., Nishiwaki M., Sakamoto T., Ishikawa T., Fairwell T., Zech L.A., Nagano M., Nakamura H., Brewer H.B. Jr, Rader D.J. Increased catabolic rate of low density lipoproteins in humans with cholesteryl ester transfer protein deficiency. J. Clin. Invest. 96:1995;1573-1581.
104. Sakai N., Yamashita S., Hirano K., Ishigami M., Arai T., Kobayashi K., Funahashi T., Matsuzawa Y. Decreased affinity of low density lipoprotein (LDL) particles for LDL receptors in patients with cholesteryl ester transfer protein deficiency. Eur. J. Clin. Invest. 25:1995;332-339.
105. Yamashita S., Ishigami M., Arai T., Sakai N., Hirano K., Kameda-Takemura K., Tokunaga K., Matsuzawa Y. Very high density lipoprotein (VHDL) induced by plasma cholesteryl ester transfer protein (CETP) have a potent anti-atherogenic function. Ann. N. Y. Acad. Sci. USA. 748:1995;606-608.
106. Francone O.L., Royer L., Haghpassand M. Increased prebeta-HDL levels, cholesterol efflux, and LCAT-mediated esterification in mice expressing the human cholesteryl ester transfer protein (CETP) and human apolipoprotein A-I (apo A-I) transgene. J. Lipid Res. 37:1996;1268-1277.
107. Atger V., de la Llera Moya M., Bamberger M., Francone O., Cosgrove P., Tall A., Walsh A., Moatti N., Rothblat G. Cholesterol efflux potential of sera from mice expressing human cholesteryl ester transfer protein and/or human apolipoprotein A-I. J. Clin. Invest. 96:1995;2613-2622.
108. Quinet E., Tall A., Ramakrishnan R., Rudel L. Plasma lipid transfer protein as a determinant of the atherogenicity of monkey plasma lipoproteins. J. Clin. Invest. 87:1991;1559-1566.
109. Sugano M., Makino N. Changes in plasma lipoprotein cholesterol levels by antisense oligodeoxynucleotides against cholesteryl ester transfer protein in cholesterol-fed rabbits. J. Biol. Chem. 271:1996;19080-19083.
110. Sugano M., Makino N., Sawada S., Otsuka S., Watanabe M., Okamoto H., Kamada M., Mizushima A. Effects of antisense oligodeoxynucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits. J. Biol. Chem. 273:1998;5033-5036.
111. Albers J.J., Tu A.-Y., Wolfbauer G., Cheung M.C., Marcovina S.M. Molecular biology of phospholipid transfer protein. Curr. Opin. Lipidol. 7:1996;88-93.
112. Kuivenhoven JA, Jukema JW, Zwinderman AH, de Knijff P, McPherson R, Bruschke AVG, Lie KI, Kastelein JJP, for the Regression Growth Evaluation Statin Study Group. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. N Engl J Med 1998;338:86-93.
113. Hirano K., Yamashita S., Kuga Y., Sakai N., Nozaki S., Kihara S., Arai T., Yanagi K., Takami S., Menju M., Ishigami M., Yoshida Y., Kameda-Takemura K., Hayashi K., Matsuzawa Y. Atherosclerotic disease in marked hyperalphalipoproteinemia; Combined reduction of cholesteryl ester transfer protein and hepatic triglyceride lipase. Arterioscler. Thromb. Vasc. Biol. 15:1995;1849-1856.
114. Hirano K., Yamashita S., Sakai N., Arai T., Yoshida Y., Nozaki S., Kameda-Takemura K., Matsuzawa Y. Molecular defect and atherogenicity in cholesteryl ester transfer protein deficiency. Ann. N. Y. Acad. Sci. 748:1995;606-608.
115. Collet X., Tall A.R., Serajuddin H., Guendouzi K., Royer L., Oliveira H., Barbaras R., Jiang X.-C., Francone O.L. Remodeling of HDL by CETP in vivo and by CETP and hepatic lipase in vitro results in enhanced uptake of HDL-CE by cells expressing scavenger receptor B-I. J. Lipid Res. 40:1999;1185-1193.
116. Hirano K., Yamashita S., Nakajima N., Arai T., Maruyama T., Yoshida Y., Ishigami M., Sakai N., Kameda-Takemura K., Matsuzawa Y. Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan; marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity. Arterioscler. Thromb. Vasc. Biol. 17:1997;1053-1059.
117. Zhong S., Sharp D.S., Grove J.S., Bruce C., Yano K., Curb J.D., Tall A.R. Increased coronary heart disease in Japanese-American men with mutations in the cholesteryl ester transfer protein gene despite increased HDL levels. J. Clin. Invest. 97:1996;2917-2923.
118. Moriyama Y., Okamura T., Inazu A., Doi M., Iso H., Mouri Y., Ishikawa Y., Suzuki H., Iida M., Koizumi J., Mabuchi H., Komachi Y. A low prevalence of coronary heart disease among subjects with increased high-density lipoprotein cholesterol levels, including those with plasma cholesteryl ester transfer protein deficiency. Prev. Med. 27:1998;659-667.
119. Bruce C., Sharp D.S., Tall A.R. Relationship of HDL and coronary heart disease to a common amino acid polymorphism in the cholesteryl ester transfer protein in men with and without hypertriglyceridemia. J. Lipid Res. 39:1998;1071-1078.
120. Agerholm-Larsen B., Nordestgaard B.G., Steffensen R., Jensen G., Tybjaerg-Hansen A. Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene. Circulation. 101:2000;1907-1912.